In:
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 55, No. 7 ( 2011-07), p. 3624-3626
Kurzfassung:
The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings.
Materialart:
Online-Ressource
ISSN:
0066-4804
,
1098-6596
DOI:
10.1128/AAC.01023-10
Sprache:
Englisch
Verlag:
American Society for Microbiology
Publikationsdatum:
2011
ZDB Id:
1496156-8
SSG:
12
SSG:
15,3